Sreedhara Alla, MD
Nephrology · Shreveport, LANPI 1215155791
Payments from drug & device makers
Across 1,409 payments — averaging $829.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$517K
- AstraZeneca$369K
- Aurinia Pharma U.S., Inc.$156K
- Travere Therapeutics, Inc.$67K
- Ardelyx, Inc.$31K
- Calliditas Therapeutics US Inc.$22K
- plus $7K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 375 | $517,091 |
| AstraZeneca(2 entities) | 422 | $369,187 |
| Aurinia Pharma U.S., Inc. | 164 | $155,570 |
| Travere Therapeutics, Inc. | 77 | $67,103 |
| Ardelyx, Inc. | 6 | $30,799 |
| Calliditas Therapeutics US Inc. | 39 | $21,669 |
| Amgen(2 entities) | 53 | $1,121 |
| Fresenius USA Marketing, Inc. | 58 | $1,063 |
| GSK | 26 | $1,049 |
| Mallinckrodt Hospital Products Inc. | 33 | $757 |
| OPKO Pharmaceuticals, LLC | 41 | $604 |
| Otsuka America Pharmaceutical, Inc. | 24 | $537 |
| Akebia Therapeutics Inc | 26 | $491 |
| Daiichi Sankyo Inc. | 14 | $264 |
| Novartis | 13 | $243 |
| Novo Nordisk | 7 | $112 |
| Vifor Pharma, Inc. | 5 | $105 |
| Shire North American Group Inc | 5 | $93 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $77 |
| Boehringer Ingelheim | 4 | $64 |
| Scpharmaceuticals Inc. | 3 | $52 |
| Sanofi | 2 | $48 |
| ANI Pharmaceuticals, Inc. | 2 | $38 |
| Mallinckrodt Enterprises LLC | 2 | $37 |
| Recor Medical Inc | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $18 |
| Veloxis Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$1,168,286 in reported general payments places this provider in the 95th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Shreveport
- Marwan KaskasShreveport$968K
- Raja ZabanehShreveport$208K
- Neville DossabhoyShreveport$166K
- Kenneth AbreoShreveport$42K
- Srinivasa IskapalliShreveport$27K
- Adrian SequeiraShreveport$18K
- Zulqarnain AbroShreveport$9K
- Cheng ChuShreveport$8K
- Arnold BarzShreveport$7K
- Christopher LuscyBaton Rouge$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.